 | MLV801 | Liver metastatic cancer tissue array, including pathology grade, TNM and clinical stage, 80 cases/80 cores | 1 Each | Sign In for Pricing | |
 | LV1221 | Liver primary cancer and metastatic cancer tissue array (most are stage IV), containing NAT sample, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, carcinoid, adenosquamous carcinoma, mixed carcinoma, metastatic carcinoma samples, 100 cases/122 cores-LV1221 | each | Sign In for Pricing | |
 | ME551 | Malignant melanoma and metastatic malignant melanoma TMA with 6 matched cancer adjacent tissue samples , including TNM and clinical stage (reference AJCC th version), 49cases/55 cores（core size 1.5mm）Recent Year Collection | 1 Each | Sign In for Pricing | |
 | BNC402225-500 | FABP5 (Marker of Metastatic Potential in Colorectal Cancer) (CPTC-FABP5-3), CF640R conjugate, 0.1mg/mL | 1x 500 µL | Sign In for Pricing | |
 | BNC403750-100 | FABP5 (Marker of Metastatic Potential in Colorectal Cancer) (FABP5/3750), CF640R conjugate, 0.1mg/mL | 1x 100 µL | Sign In for Pricing | |
 | BNC472225-100 | FABP5 (Marker of Metastatic Potential in Colorectal Cancer) (CPTC-FABP5-3), CF647 conjugate, 0.1mg/mL | 1x 100 µL | Sign In for Pricing | |
| BNC742225-100 | FABP5 (Marker of Metastatic Potential in Colorectal Cancer) (CPTC-FABP5-3), CF740 conjugate, 0.1mg/mL | 1x 100 µL | Sign In for Pricing | |
 | BNC042225-100 | FABP5 (Marker of Metastatic Potential in Colorectal Cancer) (CPTC-FABP5-3), CF405S conjugate, 0.1mg/mL | 1x 100 µL | Sign In for Pricing | |
 | BNUB2225-100 | FABP5 (Marker of Metastatic Potential in Colorectal Cancer) (CPTC-FABP5-3), 0.2mg/mL | 1x 100 µL | Sign In for Pricing | |
| GL861b | Brain metastatic cancer tissue array, including pathology grade, 43 cases/86 cores (core size 1.5mm), replacing GL861 | 1 Each | Sign In for Pricing | |
| OV802c | Ovarian cancer and metastatic adenocarcinoma tissue array with normal adjacent ovarian tissue, including pathology grade, TNM and clinical stage (AJCC 8th edition), p53 IHC, 80 cases/80 cores (core size 1.5mm) . | 1 Each | Sign In for Pricing | |
| OV208a | High density ovary cancer and ovary tissue array (1999 WHO classification), with metastatic adenocarcinoma, including pathology grade, TNM and clinical stage, 69 cases/207 cores, replacing OV208 | 69 Cases / 207 Cores | Sign In for Pricing | |
| MLV801a | Liver metastatic cancer tissue array, including pathology grade, TNM and clinical stage, 80 cases/80 cores, replacing MLV801 | 80 Cases / 80 Cores | Sign In for Pricing | |
| MBS6351924-01 | STEA2, ID (STEAP2, PCANAP1, STAMP1, Metalloreductase STEAP2, Prostate cancer-associated protein 1, Protein up-regulated in metastatic prostate cancer, Six-transmembrane epithelial antigen of prostate 2, SixTransMembrane protein of prostate 1) (MaxLight 55 | 0.1 mL | Sign In for Pricing | |
| MBS6351924-02 | STEA2, ID (STEAP2, PCANAP1, STAMP1, Metalloreductase STEAP2, Prostate cancer-associated protein 1, Protein up-regulated in metastatic prostate cancer, Six-transmembrane epithelial antigen of prostate 2, SixTransMembrane protein of prostate 1) (MaxLight 55 | 5x 0.1 mL | Sign In for Pricing | |
| AFG-ELL-1506-01 | Culture Medium for Mouse Breast Cancer High Metastatic Cells [MA-891] | 125 mL | Sign In for Pricing | |
| AFG-ELL-1506-02 | Culture Medium for Mouse Breast Cancer High Metastatic Cells [MA-891] | 500 mL | Sign In for Pricing | |
| MBS6467302-01 | CASC3, CT (Cancer Susceptibility Candidate Gene 3 Protein Homolog, Metastatic Lymph Node Protein 51 Homolog, Protein MLN 51 Homolog, Protein Barentsz, Btz, mBtz, Protein CASC3, Mln51) (MaxLight 550) | 0.1 mL | Sign In for Pricing | |
| MBS6467302-02 | CASC3, CT (Cancer Susceptibility Candidate Gene 3 Protein Homolog, Metastatic Lymph Node Protein 51 Homolog, Protein MLN 51 Homolog, Protein Barentsz, Btz, mBtz, Protein CASC3, Mln51) (MaxLight 550) | 5x 0.1 mL | Sign In for Pricing | |
| MBS6409528-01 | CASC3 (Cancer Susceptibility Candidate Gene 3 Protein Homolog, Metastatic Lymph Node Protein 51 Homolog, BTZ, MLN51) (MaxLight 405) | 0.1 mL | Sign In for Pricing | |
| MBS6409528-02 | CASC3 (Cancer Susceptibility Candidate Gene 3 Protein Homolog, Metastatic Lymph Node Protein 51 Homolog, BTZ, MLN51) (MaxLight 405) | 5x 0.1 mL | Sign In for Pricing | |
| 36-2275-20 | Anti-FABP5 (Marker of Metastatic Potential in Colorectal Cancer) Monoclonal Antibody (Clone: FABP5/3750) | 20 µg | Sign In for Pricing | |
 | C2081-30B-AP | CASC3 (Y181) (Cancer Susceptibility Candidate Gene 3 Protein Homolog, Metastatic Lymph Node Protein 51 Homolog, Protein MLN 51 Homolog, Protein Barentsz, Btz, mBtz, Protein CASC3, Mln51) (AP) discontinued | 200 µL | Sign In for Pricing | |
| 335815-01 | STEAP2 (Metalloreductase STEAP2, Prostate Cancer-Associated Protein 1, Protein up-regulated in Metastatic Prostate Cancer, PUMPCn, Six-transmembrane Epithelial Antigen of Prostate 2, SixTransmembrane Protein of Prostate 1, STEAP2, PCANAP1, STAMP1, UNQ6507/PRO2320) | 50 µg | Sign In for Pricing | |
| 335815-02 | STEAP2 (Metalloreductase STEAP2, Prostate Cancer-Associated Protein 1, Protein up-regulated in Metastatic Prostate Cancer, PUMPCn, Six-transmembrane Epithelial Antigen of Prostate 2, SixTransmembrane Protein of Prostate 1, STEAP2, PCANAP1, STAMP1, UNQ6507/PRO2320) | 100 µg | Sign In for Pricing | |
| C2081-30B-ML650 | CASC3 (Y181) (Cancer Susceptibility Candidate Gene 3 Protein Homolog, Metastatic Lymph Node Protein 51 Homolog, Protein MLN 51 Homolog, Protein Barentsz, Btz, mBtz, Protein CASC3, Mln51) (MaxLight 650) discontinued | 100 µL | Sign In for Pricing | |
| 042390-ML550 | STEA2, ID (STEAP2, PCANAP1, STAMP1, Metalloreductase STEAP2, Prostate cancer-associated protein 1, Protein up-regulated in metastatic prostate cancer, Six-transmembrane epithelial antigen of prostate 2, SixTransMembrane protein of prostate 1) (MaxLight 550) discontinued | 100 µL | Sign In for Pricing | |
| C2081-30A-ML490 | CASC3, CT (Cancer Susceptibility Candidate Gene 3 Protein Homolog, Metastatic Lymph Node Protein 51 Homolog, Protein MLN 51 Homolog, Protein Barentsz, Btz, mBtz, Protein CASC3, Mln51) (MaxLight 490) discontinued | 100 µL | Sign In for Pricing | |
| C2081-30A-Biotin | CASC3, CT (Cancer Susceptibility Candidate Gene 3 Protein Homolog, Metastatic Lymph Node Protein 51 Homolog, Protein MLN 51 Homolog, Protein Barentsz, Btz, mBtz, Protein CASC3, Mln51) (Biotin) discontinued | 200 µL | Sign In for Pricing | |
| 042390-Biotin | STEA2, ID (STEAP2, PCANAP1, STAMP1, Metalloreductase STEAP2, Prostate cancer-associated protein 1, Protein up-regulated in metastatic prostate cancer, Six-transmembrane epithelial antigen of prostate 2, SixTransMembrane protein of prostate 1) (Biotin) | 200 µL | Sign In for Pricing | |
| SM208 | Small intestine cancer, metastatic lymph nodes and normal tissue high density tissue microarray, 69 cases/208 core, with stage and grade data | 1 Each | Sign In for Pricing | |
| BL805b | Mid-advanced stage bladder cancer tissue array, with metastatic carcinoma, including pathology grade, TNM and clinical stage, 80 cases/80 cores, replacing BL805a | 1 Each | Sign In for Pricing | |
 | BNCB2225-100 | FABP5 (Marker of Metastatic Potential in Colorectal Cancer) (CPTC-FABP5-3), Biotin conjugate, 0.1mg/mL | 1x 100 µL | Sign In for Pricing | |
 | BNCB2225-500 | FABP5 (Marker of Metastatic Potential in Colorectal Cancer) (CPTC-FABP5-3), Biotin conjugate, 0.1mg/mL | 1x 500 µL | Sign In for Pricing | |
 | BNC942226-100 | FABP2 (Marker of Metastatic Potential in Colorectal Cancer) (CPTC-FABP2-3), CF594 conjugate, 0.1mg/mL | 1x 100 µL | Sign In for Pricing | |
 | BNC682226-500 | FABP2 (Marker of Metastatic Potential in Colorectal Cancer) (CPTC-FABP2-3), CF568 conjugate, 0.1mg/mL | 1x 500 µL | Sign In for Pricing | |
 | BNC042226-100 | FABP2 (Marker of Metastatic Potential in Colorectal Cancer) (CPTC-FABP2-3), CF405S conjugate, 0.1mg/mL | 1x 100 µL | Sign In for Pricing | |
 | BNC043750-100 | FABP5 (Marker of Metastatic Potential in Colorectal Cancer) (FABP5/3750), CF405S conjugate, 0.1mg/mL | 1x 100 µL | Sign In for Pricing | |
| BNC743750-500 | FABP5 (Marker of Metastatic Potential in Colorectal Cancer) (FABP5/3750), CF740 conjugate, 0.1mg/mL | 1x 500 µL | Sign In for Pricing | |
 | BNC682226-100 | FABP2 (Marker of Metastatic Potential in Colorectal Cancer) (CPTC-FABP2-3), CF568 conjugate, 0.1mg/mL | 1x 100 µL | Sign In for Pricing | |
| BNCB3750-100 | FABP5 (Marker of Metastatic Potential in Colorectal Cancer) (FABP5/3750), Biotin conjugate, 0.1mg/mL | 1x 100 µL | Sign In for Pricing | |
 | BNC042225-500 | FABP5 (Marker of Metastatic Potential in Colorectal Cancer) (CPTC-FABP5-3), CF405S conjugate, 0.1mg/mL | 1x 500 µL | Sign In for Pricing | |
| VAng-Wyb8646-inquire | Cancer Antigen CEA Antigen (Human Metastatic Liver of Colon Adenocarcinoma) | Inquire | Sign In for Pricing | |
| MBS6467304-01 | CASC3, CT (Cancer Susceptibility Candidate Gene 3 Protein Homolog, Metastatic Lymph Node Protein 51 Homolog, Protein MLN 51 Homolog, Protein Barentsz, Btz, mBtz, Protein CASC3, Mln51) (MaxLight 750) | 0.1 mL | Sign In for Pricing | |
| MBS6467304-02 | CASC3, CT (Cancer Susceptibility Candidate Gene 3 Protein Homolog, Metastatic Lymph Node Protein 51 Homolog, Protein MLN 51 Homolog, Protein Barentsz, Btz, mBtz, Protein CASC3, Mln51) (MaxLight 750) | 5x 0.1 mL | Sign In for Pricing | |
| AFG-ELL-1886 | Human Highly Metastatic Liver Cancer Cells+Luc [MHCC-97H+Luc] | > 1x 10^6 Cells / Vial | Sign In for Pricing | |
| AFG-ELL-0190 | Human High Metastatic Ovarian Cancer Cells [H0-8910PM] | > 1x 10^6 Cells / Vial | Sign In for Pricing | |
| AFG-ELL-0187 | Human High Metastatic Liver Cancer Cells [MHCC-97H] | > 1x 10^6 Cells / Vial | Sign In for Pricing | |
| NPC1541 | Nasopharyngeal carcinoma tissue microarray, containing 135 cases of nasopharyngeal carcinoma(6 cases contain matched cancer adjacent tissue), plus 12 metastatic carcinoma, single cores per block | 147 Cases / 154 Cores | Sign In for Pricing | |
| OV8010b | Mid-advanced stage ovary cancer tissue array with metastatic adenocarcinoma, including pathology grade, TNM and clinical stage, 80 cases/80 cores, replacing OV8010 | 80 Cases / 80 Cores | Sign In for Pricing | |